The first standardized pathology data set of brain tumors in China was recently released in Chongqing. This data set was independently developed by Jinfeng Laboratory. It is based on 3,420 pathological slices of brain tumors and gathers 474 typical clinical cases. It integrates CT, MRI and other imaging data, as well as genetic testing data and patient follow-up records. It has now passed the authoritative certification of the China Institute of Food and Drug Control. It is the first "official test question" in China to test AI-assisted pathological diagnosis products, and can be widely used in the testing of adult diffuse glioma auxiliary diagnostic products.

Li Sen, Project Director of Jinfeng Laboratory’s Smart Pathology Center: “AI must first learn how to treat patients, and it must pass the exam before it can take up the job. However, there has long been no nationally certified, standardized, and authoritative pathology data set to test the reliability of AI products. This has led to obstacles for many AI pathology diagnosis products to obtain medical device licenses. We just want to make up for this shortcoming. ”

It is understood that the data set released this time has not only successfully filled the gap in the domestic industry, but also provided compliant, authoritative, high-quality core data support for the research and development, registration testing, clinical verification and large-scale implementation of AI-assisted diagnosis products for brain tumors in China, and will effectively promote the standardized development of pathological diagnosis AI products. In the future, Jinfeng Laboratory will also gradually launch standardized pathological data sets for common major diseases such as lung cancer and breast cancer, which will be open to medical institutions, scientific research institutes, and formal enterprises across the country for compliant and open use.